OBJECTIVES: Traditional clinical risk factors are associated with inflammation cross-sectionally, but associations of longitudinal variation in inflammatory biomarkers with corresponding changes in clinical risk factors are incompletely described. We sought to analyze clinical factors associated with change in inflammation in the community. METHODS: We studied 3013 Framingham Offspring (n = 2735) and Omni Cohort (n = 278) participants (mean age 59 years, 55% women, 9% ethnic/racial minority) who attended two consecutive examination cycles (mean 6.7 years apart). We selected ten inflammatory biomarkers representing distinctive biological functions: C-reactive protein (CRP), intercellular adhesion molecule-1, interleukin-6, isoprostanes, lipoprotein-associated phospholipase-2 (Lp-PLA2) activity, Lp-PLA2-mass, monocyte chemoattractant protein-1, osteoprotegerin, P-selectin, and tumor necrosis factor receptor II (TNFRII). We constructed multivariable-adjusted regression models to assess the relations of baseline, follow-up and change in clinical risk factors with change in biomarker concentrations over time. RESULTS: Baseline, follow-up and change in clinical risk factors explain a moderate amount of the variation in biomarker concentrations across 2 consecutive examinations (ranging from r(2) = 0.28 [TNFRII] up to 0.52 [Lp-PLA2-mass]). In multivariable models, increasing body-mass index, smoking initiation, worsening lipid profile, and increasing waist size were associated with increasing concentrations of several biomarkers. Conversely, hypercholesterolemia therapy and hormone replacement cessation were associated with decreasing concentrations of biomarkers such as CRP, Lp-PLA2-mass and activity. CONCLUSION: Cardiovascular risk factors have different patterns of association with longitudinal change in inflammatory biomarkers and explain modest amounts of variability in biomarker concentrations. Nevertheless, a substantial proportion of longitudinal change in inflammatory markers is not explained by traditional risk factors.
OBJECTIVES: Traditional clinical risk factors are associated with inflammation cross-sectionally, but associations of longitudinal variation in inflammatory biomarkers with corresponding changes in clinical risk factors are incompletely described. We sought to analyze clinical factors associated with change in inflammation in the community. METHODS: We studied 3013 Framingham Offspring (n = 2735) and Omni Cohort (n = 278) participants (mean age 59 years, 55% women, 9% ethnic/racial minority) who attended two consecutive examination cycles (mean 6.7 years apart). We selected ten inflammatory biomarkers representing distinctive biological functions: C-reactive protein (CRP), intercellular adhesion molecule-1, interleukin-6, isoprostanes, lipoprotein-associated phospholipase-2 (Lp-PLA2) activity, Lp-PLA2-mass, monocyte chemoattractant protein-1, osteoprotegerin, P-selectin, and tumor necrosis factor receptor II (TNFRII). We constructed multivariable-adjusted regression models to assess the relations of baseline, follow-up and change in clinical risk factors with change in biomarker concentrations over time. RESULTS: Baseline, follow-up and change in clinical risk factors explain a moderate amount of the variation in biomarker concentrations across 2 consecutive examinations (ranging from r(2) = 0.28 [TNFRII] up to 0.52 [Lp-PLA2-mass]). In multivariable models, increasing body-mass index, smoking initiation, worsening lipid profile, and increasing waist size were associated with increasing concentrations of several biomarkers. Conversely, hypercholesterolemia therapy and hormone replacement cessation were associated with decreasing concentrations of biomarkers such as CRP, Lp-PLA2-mass and activity. CONCLUSION: Cardiovascular risk factors have different patterns of association with longitudinal change in inflammatory biomarkers and explain modest amounts of variability in biomarker concentrations. Nevertheless, a substantial proportion of longitudinal change in inflammatory markers is not explained by traditional risk factors.
Authors: Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy Journal: Am J Epidemiol Date: 2007-03-19 Impact factor: 4.897
Authors: Thomas J Wang; Philimon Gona; Martin G Larson; Daniel Levy; Emelia J Benjamin; Geoffrey H Tofler; Paul F Jacques; James B Meigs; Nader Rifai; Jacob Selhub; Sander J Robins; Christopher Newton-Cheh; Ramachandran S Vasan Journal: Hypertension Date: 2007-01-22 Impact factor: 10.190
Authors: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn Journal: N Engl J Med Date: 2008-11-09 Impact factor: 91.245
Authors: Renate Schnabel; Martin G Larson; Josée Dupuis; Kathryn L Lunetta; Izabella Lipinska; James B Meigs; Xiaoyan Yin; Jian Rong; Joseph A Vita; Christopher Newton-Cheh; Daniel Levy; John F Keaney; Ramachandran S Vasan; Gary F Mitchell; Emelia J Benjamin Journal: Hypertension Date: 2008-04-21 Impact factor: 10.190
Authors: Karla M Pou; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; Pal Maurovich-Horvat; Martin G Larson; John F Keaney; James B Meigs; Izabella Lipinska; Sekar Kathiresan; Joanne M Murabito; Christopher J O'Donnell; Emelia J Benjamin; Caroline S Fox Journal: Circulation Date: 2007-08-20 Impact factor: 29.690
Authors: Jennifer A Sumner; Qixuan Chen; Andrea L Roberts; Ashley Winning; Eric B Rimm; Paola Gilsanz; M Maria Glymour; Shelley S Tworoger; Karestan C Koenen; Laura D Kubzansky Journal: Biol Psychiatry Date: 2017-06-27 Impact factor: 13.382
Authors: Honghuang Lin; Roby Joehanes; Luke C Pilling; Josée Dupuis; Kathryn L Lunetta; Sai-Xia Ying; Emelia J Benjamin; Dena Hernandez; Andrew Singleton; David Melzer; Peter J Munson; Daniel Levy; Luigi Ferrucci; Joanne M Murabito Journal: Genomics Date: 2014-10-13 Impact factor: 5.736
Authors: Martha M Werler; Samantha E Parker; Klaus Hedman; Mika Gissler; Annukka Ritvanen; Heljä-Marja Surcel Journal: Am J Epidemiol Date: 2016-11-17 Impact factor: 4.897
Authors: João D Fontes; Faisal Rahman; Sean Lacey; Martin G Larson; Ramachandran S Vasan; Emelia J Benjamin; William S Harris; Sander J Robins Journal: Atherosclerosis Date: 2015-04-03 Impact factor: 5.162
Authors: Ronald Klein; Chelsea E Myers; Karen J Cruickshanks; Ronald E Gangnon; Lorraine G Danforth; Theru A Sivakumaran; Sudha K Iyengar; Michael Y Tsai; Barbara E K Klein Journal: JAMA Ophthalmol Date: 2014-04-01 Impact factor: 7.389
Authors: Madhukar S Patel; David Miranda-Nieves; Jiaxuan Chen; Carolyn A Haller; Elliot L Chaikof Journal: Transl Res Date: 2016-12-09 Impact factor: 7.012
Authors: Cassandra N Spracklen; Caitlin J Smith; Audrey F Saftlas; Elizabeth W Triche; Andrew Bjonnes; Brendan J Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman Journal: Hypertens Pregnancy Date: 2016-09-22 Impact factor: 2.108
Authors: Cari M Kitahara; Britton Trabert; Hormuzd A Katki; Anil K Chaturvedi; Troy J Kemp; Ligia A Pinto; Steven C Moore; Mark P Purdue; Nicolas Wentzensen; Allan Hildesheim; Meredith S Shiels Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-23 Impact factor: 4.254
Authors: Joanne M Murabito; Qiang Zhao; Martin G Larson; Jian Rong; Honghuang Lin; Emelia J Benjamin; Daniel Levy; Kathryn L Lunetta Journal: J Gerontol A Biol Sci Med Sci Date: 2018-05-09 Impact factor: 6.053
Authors: Wenyuan Li; Marguerite M Nyhan; Elissa H Wilker; Carolina L Z Vieira; Honghuang Lin; Joel D Schwartz; Diane R Gold; Brent A Coull; Abdulaziz Mansour Aba; Emelia J Benjamin; Ramachandran S Vasan; Petros Koutrakis; Murray A Mittleman Journal: Environ Int Date: 2018-10-28 Impact factor: 9.621